Molecularly targeted therapies for glioma

Ryuya Yamanaka, Hideyuki Saya

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Over the past decade, molecularly targeted therapies have been added to cytotoxic and antiendocrine drugs in the treatment of cancer, with the aim of targeting the molecular pathways that underlie the carcinogenic process and maintain the cancer phenotype. Success with some of these agents has suggested that identification and validation of drug targets is the starting point for the development of active, safe, and effective drugs. The main molecular targets used to develop anticancer drugs are cell surface receptors, signal transduction pathways, gene transcription targets, ubiquitin-proteasome/heat shock proteins, and tumor micro-environment components. Here, we review the development of the main molecularly targeted noncytotoxic agents studied in glioma, highlighting lessons derived from the development of these novel drugs and proposing new horizons for the clinical development of molecularly targeted therapies.

Original languageEnglish
Pages (from-to)717-729
Number of pages13
JournalAnnals of Neurology
Volume66
Issue number6
DOIs
Publication statusPublished - 2009 Dec

    Fingerprint

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this